Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions

NCT03629379 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Inflammatory Bowel Diseases
Psoriasis

Interventions

DRUG: Ustekinumab
DRUG: Vedolizumab

Sponsor

Universitaire Ziekenhuizen KU Leuven